Wockhardt receives QIDP designation for its new drug WCK 4873 from USFDA

22 May 2015 Evaluate

Wockhardt has received Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from USFDA. The US Food and Drug Administration (USFDA) has granted WCK 4873, a product from their New Drug Discovery program, Qualified Infectious Disease Product (QIDP) status.

This is the third product from Wockhardt to receive this coveted status after WCK 771 and WCK 2349 last year and provides a strong boost to its drug development program.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.



Wockhardt Share Price

1292.45 61.50 (5.00%)
25-Nov-2024 12:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.85
Dr. Reddys Lab 1222.00
Cipla 1504.95
Lupin 2111.00
Zydus Lifesciences 958.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.